The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein e knockout mice

Diabetologia

Volumn 53, Issue 1, 2010, Pages 192-203

  Watson, A M D ^a   Li, J ^a   Schumacher, C ^b   De Gasparo, M ^c   Feng, B ^a   Thomas, M C ^a   Allen, T J ^a   Cooper, M E ^a   Jandeleit Dahm, K A M ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MG Consulting Co   (Switzerland)

Author keywords

ACE inhibition; Diabetes mellitus; Diabetic complications; Endothelin; Kidney disease; Mouse model

Indexed keywords

3 NITROTYROSINE; ANGIOTENSIN RECEPTOR; APOLIPOPROTEIN E; AVOSENTAN; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; DRINKING WATER; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO; QUINAPRIL; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CELL INFILTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MEGADOSE; GENE EXPRESSION; GLOMERULOSCLEROSIS; LOW DRUG DOSE; MACROPHAGE; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; STREPTOZOCIN DIABETES;

ANIMALS; ANTIHYPERTENSIVE AGENTS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; HYPERGLYCEMIA; HYPERLIPIDEMIAS; KIDNEY; KIDNEY FUNCTION TESTS; MICE; MICE, KNOCKOUT; PYRIDINES; PYRIMIDINES; RECEPTORS, ENDOTHELIN; TETRAHYDROISOQUINOLINES;

EID: 72449124626     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-009-1540-3     Document Type: Article

References (44)

1. W Neuhofer D Pittrow 2006 Role of endothelin and endothelin receptor antagonists in renal disease Eur J Clin Invest 36 Suppl 3 78 88 10.1111/j.1365-2362.2006.01689.x 1:CAS:528:DC%2BD28XhtVeqtLrM 16919017 (Pubitemid 44179788)
2. B Hocher C Thone-Reineke P Rohmeiss, et al. 1997 Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension J Clin Invest 99 1380 1389 10.1172/JCI119297 1:CAS:528: DyaK2sXitVWlurw%3D 9077548
3. JH Warram LJ Scott LS Hanna, et al. 2000 Progression of microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia Diabetes 49 94 100 10.2337/diabetes.49.1.94 1:CAS:528:DC%2BD3cXkt1ygsw%3D%3D 10615955
4. T Nakamura I Ebihara M Fukui Y Tomino H Koide 1995 Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli Diabetes 44 895 899 10.2337/diabetes.44.8.895 1:CAS:528:DyaK2MXnsVSnsbc%3D 7621993
5. B Hocher A Schwarz D Reinbacher, et al. 2001 Effects of endothelin receptor antagonists on the progression of diabetic nephropathy Nephron 87 161 169 10.1159/000045906 1:CAS:528:DC%2BD3MXit1ensbY%3D 11244312 (Pubitemid 32215829)
6. S Dhein S Hochreuther C Aus Dem Spring K Bollig C Hufnagel M Raschack 2000 Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model J Pharmacol Exp Ther 293 351 359 1:CAS:528:DC%2BD3cXkvFWgsLw%3D 10773002
7. S Chen T Evans D Deng M Cukiernik S Chakrabarti 2002 Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins Nephron 90 86 94 10.1159/000046319 1:CAS:528:DC%2BD3MXptFClt78%3D 11744810 (Pubitemid 34042846)
8. JM Forbes TD Hewitson GJ Becker CL Jones 2001 Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function Kidney Int 59 1333 1341 10.1046/j.1523-1755.2001. 0590041333.x 1:CAS:528:DC%2BD3MXjtVOht7c%3D 11260394 (Pubitemid 32281221)
9. W Dieterle J Mann K Kutz 2004 Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects J Clin Pharmacol 44 59 66 10.1177/0091270003261047 1:CAS:528: DC%2BD2cXls1OjsQ%3D%3D 14681342 (Pubitemid 38005094)
10. RR Wenzel T Littke S Kuranoff, et al. 2009 Avosentan reduces albumin excretion in diabetics with macroalbuminuria J Am Soc Nephrol 20 655 664 10.1681/ASN.2008050482 19144760
11. M Lassila KK Seah TJ Allen, et al. 2004 Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end products J Am Soc Nephrol 15 2125 2138 10.1097/01.ASN.0000133025.23732.46 1:CAS:528:DC%2BD2cXlvVKmu7o%3D 15284298 (Pubitemid 39031351)
12. J Tse B Martin-McNaulty M Halks-Miller, et al. 1999 Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17 beta-estradiol Atherosclerosis 144 303 313 10.1016/S0021-9150(98)00325-6 1:CAS:528:DyaK1MXjtl2qsrk%3D 10407491 (Pubitemid 29305464)
13. B Battistini N Berthiaume NF Kelland DJ Webb DE Kohan 2006 Profile of past and current clinical trials involving endothelin receptor antagonists: the NOVEL 'Sentan' class of drug Exp Biol Med (Maywood) 231 653 695 1:CAS:528:DC%2BD28Xlt1eku70%3D
14. JH Krege JB Hodgin JR Hagaman O Smithies 1995 A noninvasive computerized tail-cuff system for measuring blood pressure in mice Hypertension 25 1111 1115 1:STN:280:DyaK2M3lsF2jtQ%3D%3D 7737724
15. R Candido KA Jandeleit-Dahm Z Cao, et al. 2002 Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice Circulation 106 246 253 10.1161/01.CIR. 0000021122.63813.32 1:CAS:528:DC%2BD38XmtFWmtr0%3D 12105166 (Pubitemid 34761307)
16. R Candido TJ Allen M Lassila, et al. 2004 Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis Circulation 109 1536 1542 10.1161/01.CIR.0000124061.78478.94 1:CAS:528:DC%2BD2cXisVGmsbg%3D 15023892 (Pubitemid 38420183)
17. A Soro-Paavonen AMD Watson J Li, et al. 2008 Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes Diabetes 57 2461 2469 10.2337/db07-1808 1:CAS:528:DC%2BD1cXhtFSrtrnP 18511846
18. K Jandeleit-Dahm TJ Allen S Youssef RE Gilbert ME Cooper 2000 Is there a role for endothelin antagonists in diabetic renal disease? Diabetes Obes Metab 2 15 24 10.1046/j.1463-1326.2000.00045.x 1:CAS:528:DC%2BD3cXjslSms7k%3D 11220349 (Pubitemid 33076772)
19. MA Khan MR Dashwood FH Mumtaz CS Thompson DP Mikhailidis RJ Morgan 1999 Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy Nephron 83 261 267 10.1159/000045519 1:CAS:528:DyaK1MXntVansb0%3D 10529633 (Pubitemid 29486405)
20. AJ King BM Brenner S Anderson 1989 Endothelin: a potent renal and systemic vasoconstrictor peptide Am J Physiol Renal Physiol 256 F1051 F1058 1:CAS:528:DyaL1MXksFWhsrY%3D
21. AC Calkin S Giunti KA Jandeleit-Dahm TJ Allen ME Cooper MC Thomas 2006 PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse Nephrol Dial Transplant 21 2399 2405 10.1093/ndt/gfl212 1:CAS:528:DC%2BD28XhtVWltrfL 16720596 (Pubitemid 44644510)
22. D Gomez-Garre R Largo N Tejera J Fortes F Manzarbeitia J Egido 2001 Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria : role of angiotensin II and endothelin-1 Hypertension 37 1171 1178 1:CAS:528:DC%2BD3MXjtFCgt70%3D 11304520
23. K Jandeleit-Dahm M Lassila BJ Davis, et al. 2005 Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice J Hypertens 23 2071 2082 10.1097/01.hjh.0000184747.41565.a1 1:CAS:528:DC%2BD2MXhtVOitLbK 16208151
24. MW Steffes RW Bilous DER Sutherland SM Mauer 1992 Cell and matrix components of the glomerular mesangium in type I diabetes Diabetes 41 679 684 10.2337/diabetes.41.6.679 1:STN:280:DyaK383mslamsQ%3D%3D 1587395
25. ME Cooper TJ Allen PA Macmillan BE Clarke G Jerums AE Doyle 1989 Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat Diabetologia 32 326 328 10.1007/BF00265552 1:CAS:528: DyaL1MXkvFShsrs%3D 2546846
26. M Mauer B Zinman R Gardiner, et al. 2009 Renal and retinal effects of enalapril and losartan in type 1 diabetes N Engl J Med 361 40 51 10.1056/NEJMoa0808400 1:CAS:528:DC%2BD1MXotV2hu70%3D 19571282
27. B Rizkalla JM Forbes Z Cao G Boner ME Cooper 2005 Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system J Hypertens 23 153 164 10.1097/00004872-200501000-00026 1:CAS:528:DC%2BD2MXitVChtw%3D%3D 15643138 (Pubitemid 40128994)
28. M Lassila K Jandeleit-Dahm KK Seah, et al. 2005 Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice J Am Soc Nephrol 16 363 373 10.1681/ASN.2004050392 1:CAS:528:DC%2BD2MXhvVCksLo%3D 15625075 (Pubitemid 41725131)
29. K Susztak E Bottinger A Novetsky, et al. 2004 Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease Diabetes 53 784 794 10.2337/diabetes.53.3.784 1:CAS:528:DC%2BD2cXhvFeks74%3D 14988265 (Pubitemid 38270650)
30. H Yamaguchi M Igarashi A Hirata, et al. 2004 Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients Endocr J 51 499 504 10.1507/endocrj.51.499 1:CAS:528:DC%2BD2MXlvVOlsw%3D%3D 15516785 (Pubitemid 39536359)
31. D Bruemmer AR Collins G Noh, et al. 2003 Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice J Clin Invest 112 1318 1331 1:CAS:528:DC%2BD3sXovVGqsrc%3D 14597759
32. J Lorenzen R Shah A Biser, et al. 2008 The role of osteopontin in the development of albuminuria J Am Soc Nephrol 19 884 890 10.1681/ASN.2007040486 1:CAS:528:DC%2BD1cXmtlOhu7g%3D 18443355
33. A Sorokin DE Kohan 2003 Physiology and pathology of endothelin-1 in renal mesangium Am J Physiol Renal Physiol 285 F579 F589 1:CAS:528: DC%2BD3sXosVKis70%3D 12954590
34. D Gomez-Garre M Ruiz-Ortega M Ortego, et al. 1996 Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth Hypertension 27 885 892 1:CAS:528:DyaK28Xis1Ors7c%3D 8613264
35. SR Orth C Viedt K Amann E Ritz 2001 Endothelin in renal diseases and cardiovascular remodeling in renal failure Intern Med 40 285 291 10.2169/internalmedicine.40.285 1:CAS:528:DC%2BD3MXltV2ku78%3D 11334385 (Pubitemid 33606171)
36. DJ Leehey AK Singh N Alavi R Singh 2000 Role of angiotensin II in diabetic nephropathy Kidney Int Suppl 77 S93 S98 10.1046/j.1523-1755.2000.07715. x 1:CAS:528:DC%2BD3cXms1Oiu7o%3D 10997697
37. J Goddard NR Johnston MF Hand, et al. 2004 Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade Circulation 109 1186 1193 10.1161/01.CIR. 0000118499.69469.51 1:CAS:528:DC%2BD2cXhs12kt7w%3D 14981006 (Pubitemid 38332625)
38. JC Spratt J Goddard N Patel FE Strachan AJ Rankin DJ Webb 2001 Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men Br J Pharmacol 134 648 654 10.1038/sj.bjp.0704304 1:CAS:528:DC%2BD3MXnvV2ku74%3D 11588120
39. JM Sasser JC Sullivan JL Hobbs, et al. 2007 Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism J Am Soc Nephrol 18 143 154 10.1681/ASN.2006030208 1:CAS:528:DC%2BD2sXht1Kqtr4%3D 17167119 (Pubitemid 46053429)
40. M Barton CC Haudenschild LV d'Uscio S Shaw K Munter TF Luscher 1998 Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice Proc Natl Acad Sci U S A 95 14367 14372 10.1073/pnas.95.24.14367 1:CAS:528:DyaK1cXns1Gls7g%3D 9826706 (Pubitemid 28549373)
41. SR Orth G Odoni K Amann P Strzelczyk M Raschack E Ritz 1999 The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the 'Fisher to Lewis' model J Am Soc Nephrol 10 387 391 1:CAS:528:DyaK1MXht1Wgt7o%3D 10215340
42. G Fukuda ZA Khan YP Barbin H Farhangkhoee RG Tilton S Chakrabarti 2005 Endothelin-mediated remodeling in aortas of diabetic rats Diabetes Metab Res Rev 21 367 375 10.1002/dmrr.527 1:CAS:528:DC%2BD2MXnsl2qtbw%3D 15580650 (Pubitemid 40945959)
43. Y Nakashima AS Plump EW Raines JL Breslow R Ross 1994 ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree Arterioscler Thromb 14 133 140 1:CAS:528:DyaK2cXivFGlsro%3D 8274468
44. K Jandeleit-Dahm A Watson A Soro-Paavonen, et al. 2008 The novel endothelin receptor A (ET-A) antagonist SPP 301 attenuates albuminuria and renal structural injury in streptozotocin-induced diabetic ApoE knockout mice J Hypertens 26 S194 abstract